Currently Viewing:
Currently Reading
CheckMate-026 Fails in Phase 3 - Nivolumab Monotherapy Does Not Improve PFS in NSCLC
August 05, 2016 – Surabhi Dangi-Garimella, PhD
Knowing Which RCC Patients Do Not Qualify for Nivolumab Treatment
August 04, 2016 – Surabhi Dangi-Garimella, PhD
Avalere Health Projects Outpatient Spending Biggest Driver of 2017 Premium Increases
August 04, 2016 – Surabhi Dangi-Garimella, PhD
Foundation Medicine Applies for Parallel FDA and CMS Review for CGP Test
August 03, 2016 – AJMC Staff
Nivolumab Passes QOL Test in Melanoma
August 03, 2016 – Surabhi Dangi-Garimella, PhD
More Than Half of Patients Misuse Prescription Drugs, Study Finds
August 02, 2016 – Jackie Syrop
The Risk of T2D in Individuals With Benign Adrenal Tumors
August 02, 2016 – AJMC Staff
What We're Reading: Colorado Asks Sanders to Help With Its Universal Healthcare Proposal
August 01, 2016 – AJMC Staff
Research and Clinical Updates on World Lung Cancer Day
August 01, 2016 – Surabhi Dangi-Garimella, PhD

CheckMate-026 Fails in Phase 3 - Nivolumab Monotherapy Does Not Improve PFS in NSCLC

Surabhi Dangi-Garimella, PhD
Nivolumab failed to perform better than chemotherapy in patients with squamous as well as non-squamous non-small cell lung cancer (NSCLC).
Bristol Myer Squibb (BMS)’s recent immunotherapy success, nivolumab (Opdivo), failed to improve progression-free survival (PFS) when given alone to treatment-naïve patients with non-small cell lung cancer (NSCLC) whose tumors expressed at least 5% of the biomarker programmed death-ligand 1 (PD-L1).

The trial was designed to evaluate the programmed death-1 (PD-1) inhibitor nivolumab as monotherapy against investigator’s choice of chemotherapy in patients with NSCLC. The trial enrolled 541 treatment-naïve patients whose tumors expressed PD-L1; patients were randomized to receive either a 3 mg/kg intravenous infusion of nivolumab, every 2 weeks or the physician’s choice of a chemotherapy agent. For patients with squamous NSCLC, the comparator treatment was one of the following:
  • Gemcitabine with cisplatin
  • Gemcitabine with carboplatin
  • Paclitaxel with carboplatin
In patients with non-squamous NSCLC, the comparator treatment was one of the following:
  • Pemetrexed with cisplatin
  • Pemetrexed with carboplatin
The trial endpoint was disease progression, unacceptable toxicity, or completion of 6 cycles of treatment. The primary endpoint was PFS.

Despite these disappointing results, chief executive officer Giovanni Caforio, MD, is hopeful about the other combination treatment trials that BMS is pursuing simultaneously.

“Opdivo has become a foundational treatment that is transforming cancer care across multiple tumor types. While we are disappointed CheckMate -026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase 3 CheckMate-227 study exploring the potential of the combination of Opdivo plus Yervoy for PD-L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD-L1 negative patients,” Caforio said in a press release.

BMS stock fell 16% following the news early Friday, while the price of its competitor, Merck, rose nearly 7%, according to Bloomberg. Merck manufacturer’s the other PD-1 inhibitor pembrolizumab (Keytruda).

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up